DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 152,300 shares, an increase of 10.0% from the September 15th total of 138,400 shares. Based on an average daily volume of 54,000 shares, the days-to-cover ratio is presently 2.8 days.

DiaMedica Therapeutics Stock Down 2.5 %

Shares of NASDAQ DMAC traded down $0.11 during midday trading on Thursday, hitting $4.29. The stock had a trading volume of 24,808 shares, compared to its average volume of 50,969. The business’s 50 day moving average is $4.09 and its 200-day moving average is $3.32. DiaMedica Therapeutics has a 52 week low of $2.05 and a 52 week high of $4.95. The company has a market cap of $183.36 million, a P/E ratio of -7.66 and a beta of 1.48.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. During the same quarter in the previous year, the business earned ($0.16) earnings per share. As a group, analysts expect that DiaMedica Therapeutics will post -0.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright initiated coverage on DiaMedica Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $7.00 price objective for the company. Oppenheimer restated an “outperform” rating and set a $6.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 16th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DiaMedica Therapeutics stock. Magnolia Capital Advisors LLC acquired a new stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 29,500 shares of the company’s stock, valued at approximately $87,000. Magnolia Capital Advisors LLC owned about 0.07% of DiaMedica Therapeutics as of its most recent SEC filing. 10.12% of the stock is currently owned by institutional investors and hedge funds.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.